{
    "organizations": [],
    "uuid": "462db2489b78c2916dbd7707fbc5a1bd46c08a3d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mei-pharma-says-interim-data-revie/brief-mei-pharma-says-interim-data-review-supports-continuation-of-me-344-clinical-study-idUSFWN1Q30ZD",
    "ord_in_thread": 0,
    "title": "MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - MEI Pharma Inc:\n* MEI PHARMA INTERIM DATA REVIEW SUPPORTS CONTINUATION OF CLINICAL STUDY EVALUATING ME-344 IN PATIENTS WITH BREAST CANCER\n* MEI PHARMA INC - INTERIM STUDY DATA SHOW THAT ME-344 WAS GENERALLY WELL-TOLERATED\n* MEI PHARMA - BASED ON INTERIM STUDY RESULTS, IT WAS DETERMINED THAT COMPLETING ENROLLMENT OF STUDY OF ME-344 IN COMBINATION WITH BEVACIZUMAB IS WARRANTED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T21:13:00.000+02:00",
    "crawled": "2018-02-14T12:17:54.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "mei",
        "pharma",
        "inc",
        "mei",
        "pharma",
        "interim",
        "data",
        "review",
        "support",
        "continuation",
        "clinical",
        "study",
        "evaluating",
        "patient",
        "breast",
        "cancer",
        "mei",
        "pharma",
        "inc",
        "interim",
        "study",
        "data",
        "show",
        "generally",
        "mei",
        "pharma",
        "based",
        "interim",
        "study",
        "result",
        "determined",
        "completing",
        "enrollment",
        "study",
        "combination",
        "bevacizumab",
        "warranted",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}